У нас вы можете посмотреть бесплатно Bioharvest Sciences (BHST) CEO Ilan Sobel Record 2024 Results: 99% revenue growth to $25.2 million или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com. @BioHarvestBHSC $BHST #BHST #8MV0 #bioharvest #botanicalsynthesis #biotech #pharmaceuticals #nutraceuticals #plantbasedwellness https://bioharvest.com/ Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward-looking statements. Please read the presenting companies' forward-looking statement disclaimers.